Every article, report, and earnings note where GILD appears.
ARIAD Pharmaceuticals, Inc. (NYSE: ARIA) is expected to list on 2026-08-10, but the price range has not been disclosed. The key question is not valuation yet—it is whether this is a real upcoming IPO filing or a historical company reference that still needs confirmation. Bull case: a recognizable biotech name; bear case: the current offering details are not yet verified.
Gilead Sciences, Inc. (GILD) gains after a stronger-than-expected earnings report, but the real story is deeper than the headline beat. This analysis breaks down revenue momentum, HIV and Yeztugo growth, acquisition-related charges, and what the latest guidance means for the stock.
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Gilead Sciences, Inc. (GILD) gains 2.6% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.
Obsidian Therapeutics, Inc. Common Stock (NASDAQ: OBX) is expected to list on 2026-08-04, but the price range has not been disclosed. The company is coming to market through an all-stock reverse merger with Galera Therapeutics rather than a traditional IPO. Bull case: a differentiated cell-therapy platform with strong strategic backing; bear case: no disclosed pricing, no commercial revenue, and heavy clinical risk.
Seven biotech stocks ranked by investment quality — Regeneron, Vertex, and Axsome all make the list, with the top two spots saved for the countdown's finish.
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate GILD ReportCancel anytime